HB3269, the Eliminating Thickets to Increase Competition Act or “ETHIC Act,” would amend the federal patent infringement statute to limit how many patents can be asserted in a single infringement action against certain drug and biologic applicants or manufacturers. Specifically, in cases involving abbreviated new drug applications, biosimilar applications, or approved products under those pathways, a plaintiff could assert no more than one patent per defined “Patent Group” in an action under 35 U.S.C. 271(e). The bill defines a Patent Group as two or more commonly owned patents or applications linked through terminal disclaimers, and it bars additional actions against the same party on other patents in the same group.
The practical effect is to reduce the ability of brand-name pharmaceutical and biologic patent holders to bring multiple, overlapping lawsuits based on related patents in order to delay market entry by generic and biosimilar competitors. The amendment would apply only to applications submitted on or after enactment, and it would change federal patent litigation rules rather than FDA approval standards or the underlying patent term itself. Its focus is on competition in the pharmaceutical and biologics markets, especially where patent portfolios are used to create “patent thickets.”
The bill appears to have bipartisan sponsorship and, based on the limited available context, no recorded committee debate or votes yet. The introduction by members from both parties suggests a generally reform-oriented and cross-party interest in addressing drug pricing and competition concerns. Because there is no transcript or vote history provided, there is no evidence of formal opposition in the available record, but the bill’s subject matter typically draws interest from both consumer advocates and industry stakeholders.
The main point of contention is likely to be whether the bill appropriately curbs abusive litigation tactics without weakening legitimate patent protections for innovative drug and biologic development. Supporters would likely view the measure as a way to speed generic and biosimilar competition and lower costs, while opponents may argue that limiting the number of asserted patents could undercut enforcement of valid intellectual property rights and reduce incentives for research and development. The bill’s narrow focus on patent groups tied to terminal disclaimers suggests an attempt to target perceived abuse rather than broadly rewrite patent law.
Impact
HB3269 would amend 35 U.S.C. 271(e) to restrict patent holders in certain pharmaceutical and biologic infringement suits to asserting only one patent per “Patent Group” against specified generic drug and biosimilar applicants or manufacturers. It would affect patent litigation strategy in cases involving abbreviated new drug applications under FDCA section 505(b)(2) or (j) and biosimilar applications under PHS Act section 351(k), while leaving FDA approval pathways and patent validity rules otherwise intact. The change would apply prospectively to applications submitted on or after enactment.
Sentiment
The available context suggests a generally favorable, reform-minded sentiment around the bill, with bipartisan sponsorship indicating interest across party lines in addressing patent thickets and competition barriers in pharmaceuticals. No committee transcripts or votes are provided, so there is no recorded formal debate in the supplied materials. Based on the bill’s purpose, support would likely center on competition and lower drug costs, while concerns would likely come from patent holders and industry groups worried about reduced enforcement leverage.
Contention
The central contention is between efforts to curb alleged patent thickets and concerns about preserving robust patent enforcement. Supporters are likely to argue that limiting multiple assertions from the same patent family or group will prevent strategic litigation designed to delay generic and biosimilar entry. Opponents are likely to contend that the bill could sweep too broadly, making it harder for innovators to protect legitimate, distinct patents and potentially weakening incentives for pharmaceutical and biologic research. The bill’s use of terminal disclaimers to define a Patent Group may also be a technical point of dispute.